Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Choosing the right credit card for travel rewards can be challenging. Find out which options provide the best benefits for you.
27,921 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A midstream-focused energy ETF aims to deliver reliable income through toll-road style fees rather than volatile comm...
Rigetti's Q1 earnings tonight could shape the next move for its stock as Novera shipments and Cepheus milestones feed...
Ford shares jumped roughly 7% as Q1 momentum and Ford Pro strength lifted the full-year EBIT outlook, putting Ford ah...
JPMorgan boosted Hewlett Packard Enterprise's price target to $37, citing easing memory costs and improving earnings ...
Panorama Mortgage Group is folding its various brands into a single banner, SimplyPMG, and naming Fernando Ospina as ...
Galaxy Research analyst Alex Thorn lifts the odds of the CLARITY Act becoming law in 2026 to 75%, citing a pivotal Se...
Banks assert that deposits remain protected as AI advances. This report surveys safeguards, evolving risks, and pract...
XRP tests the $1.40 support as bulls fight for momentum. Here are the three signals shaping its path this week.
SpaceX’s long-anticipated S-1 lays out revenue and losses, yet key subscription and launch-cost details are absent, c...
SpaceX going public could redefine the balance of big-name holdings in passive portfolios. This guide explains what b...
SMCI and Gorilla Technology stock fell sharply after a $2 billion India AI infrastructure deal. Investors are weighin...